High Flow Nasal Oxygen Therapy Usage in the Adult Intensive Care Units in Turkey: Multi-center, Prospective Study
Bildiriler > Özet Bildiri
Yazarlar: Fatma Bodur Yildirim, Serpil Öcal, Ebru Ersoy Ortac, Ömer Zühtü Yöndem, Barıs Ecevit Yüksel, Turkay Akbas, Oner Abidin Balbay, Emre Aydın, Fatma Yılmaz Aydın, Nilgün Alptekinoglu Mendil, Sema Turan, Hayriye Cankar Dal, Yalım Dikmen, Elif Erdoğan, Serdar Akpınar, Gülbin Aygencel, Melda Türkoglu, Nur Karaaslan, Seval İzdes, Hicran Özdemir Demir, Nimet Senoglu, Burcu Sayan, Cenk Kıraklı, Rahime Aydın Kayalı, Pervin Korkmaz, Feza Bacakoglu, Filiz Kosar
Acute critical care, , , Uluslararası, Özet Bildiri, ss PA4020-PA4020
DOI: 10.1183/13993003.congress-2019.pa4020
Özet
Aim: High flow nasal oxygen (HFNO) is widely used all over the world as oxygen support therapy. In our study, we aimed to evaluate the clinical characteristics of the patients treated with HFNO therapy, indications and results of HFNO therapy in adult ICUs of Turkey. Method: This multicenter, prospective, observational was conducted between 15 January 2018 and 15 January 2019 and included 14 centers. Results: The study included 298 patients with a mean age of 65.8±17.1 years, 172 (57.7%) of the patients were male. APACHE II and SOFA scores were 22.5±7.8 and 5.8±3.4 respectively. The mean respiratory rate of the patients at the onset of HFNO was 26.2±7.6 breaths/min, SpO2 89.3±8.2% and median Dyspnea score was 7. Most common indication for the use of HFNO was respiratory failure in 220 (73.8%) patients. Other indications were the risk of post-operative respiratory failure in 57 (29.8%) patients, palliative purposes in 17 (5.7%) patients. Type 1 hypoxemic respiratory failure was most common reason for respiratory failure (70.8%). Median HFNO administration time 4 [1-21] days, median initial flow rate was 54 L/min, and median initiation FiO2 was 60%. Initial respiratory rate (p<0.001), heart rate (p<0.001), dyspnoea score (p<0.001) and SpO2 (p<0.001) showed significant improvement in patients treated with HFNO. The median comfort score was 6 during HFNO. Out of 53.7 % of patients experienced at least one discomfort during HFNO therapy. The most common discomforts were high temperature with 32.2%. nasal discomfort with 15.8%. Mortality of patients receiving HFNO therapy was 34.9%. The indications for use of HFNO in our country vary widely, HFNO therapy seems to be benefical in many aspects.